DeCure for Uterine corpus atypical polypoid adenomyoma
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for uterine corpus atypical polypoid adenomyoma — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleUterine corpus atypical polypoid adenomyoma maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for uterine corpus atypical polypoid adenomyoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
KRas proto-oncogene, GTPase (KRAS) — KRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7VVB · 1.7 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
A systematic review of 237 patients from eleven retrospective studies found that atypical polypoid adenomyoma coexisted with atypical hyperplasia in 5.5% of cases and with endometrial cancer in 5.9%. Overall risks of recurrence and progression to cancer were 28.9% and 16.6%, respectively. Transcervical resection showed significantly higher initial response rates than any other fertility-sparing treatment, and transcervical resection with or without hormonal therapy showed significantly lower progression rates and higher final complete response rates. No significant differences were found in pregnancy or recurrence rates between treatments. Among resection techniques, the 4-step method showed significantly lower rates of progression and recurrence than other techniques.
A separate retrospective study of 39 cases reported a median age of 39.6 years, with 94.9% premenopausal and 46.2% nulliparous. Concurrent atypical endometrial hyperplasia was found in 23.1% of cases and concurrent endometrial carcinoma in 7.7%. Among 20 patients who received fertility-preserving treatment, pregnancy success was 15% and live birth frequency was 10%. Over a median follow-up of 48.1 months, pathological recurrence and progression to endometrial carcinoma were both 5%. One patient died of another malignancy.
A sonographic study of 32 patients with polypoid adenomyomas (not specifically atypical) identified three patterns: solid, solid with cystic areas, and predominantly cystic. Features included a heterogeneously isoechoic, polypoid endometrial mass with ill-defined margin, hemorrhagic foci, posterior shadowing, and associated adenomyosis.
All evidence is retrospective and based on small sample sizes due to the rarity of the condition. No prospective trials exist. What is missing is a standardised prospective registry or randomised trial comparing resection techniques and long-term fertility outcomes, and reliable biomarkers to stratify patients by risk of concurrent carcinoma or progression.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Acta Obstetricia Et Gynecologica Scandinavica · 2019 · 67 citations · open access
Management of women with atypical polypoid adenomyoma of the uterus: A quantitative systematic review
AbstractINTRODUCTION: Atypical polypoid adenomyoma is an uncommon uterine lesion which can coexist with endometrial atypical hyperplasia and/or cancer. Atypical polypoid adenomyoma affects premenopausal women in most cases, but it shows high recurrence rate if conservatively treated. To date, the management of patients is based on low-quality evidence and is not standardized. Our primary aim was to explore the optimal management of atypical polypoid adenomyoma, with particular regard to the fertility-sparing approach. The secondary aim was to define clinicopathologic features of atypical polypoid adenomyoma. MATERIAL AND METHODS: Medline, Embase, Web of Sciences, Scopus, ClinicalTrial.gov, OVID, Google Scholar and Cochrane Library were searched for studies reporting outcomes of atypical polypoid adenomyoma treatments. Univariate comparisons among outcomes of fertility-sparing treatments (rates of initial response, progression, recurrence, final complete response, pregnancy) were performed with Fisher's exact test (α = .05). RESULTS: Eleven retrospective studies with 237 patients were included; 85.5% of patients were premenopausal and 62.9% were nulliparous. Atypical polypoid adenomyoma coexisted with atypical hyperplasia in 5.5% of cases and with endometrial cancer in 5.9%. Overall risks of recurrence and progression to cancer were 28.9% and 16.6%, respectively. Fertility-sparing treatments included hormonal therapy with or without maintenance, hysteroscopic transcervical resection, dilation and curettage, and hormonal therapy combined with transcervical resection or dilation and curettage. Transcervical resection showed significantly higher initial response rates (P from <0.001 to 0.023) than any other treatment. Transcervical resection and transcervical resection+hormonal therapy showed significantly lower progression rates (P < 0.001), and higher final complete response rates (P < 0.001) than any other treatment. No significant differences were found in the rates of pregnancy (P = 0.533 - 0.647) or recurrence (P = 0.052 - 0.475). Among the different transcervical resection techniques, the 4-step transcervical resection showed significantly lower rates of progression (P = 0.002) and recurrence (P = 0.013) than other techniques. Limitations to our results were the retrospective design of the studies and the relatively small sample size, due to the rarity of atypical polypoid adenomyoma. CONCLUSIONS: Based on its effectiveness and safety, transcervical resection may be the first-line fertility-sparing treatment for atypical polypoid adenomyoma. In particular, 4-step transcervical resection showed the best results. Given the risk of recurrence, progression and coexistent atypical hyperplasia or cancer, follow-up biopsies are advisable. When fertility preservation is not required, hysterectomy might be advisable.
Sonographic Findings of Uterine Polypoid Adenomyomas
AbstractBased on a retrospective analysis of 32 patients with polypoid adenomyomas of the uterus, the authors have identified 3 sonographic patterns: solid (pattern 1, 8 cases), solid with cystic areas (pattern 2, 22 cases), and predominantly cystic (pattern 3, 2 cases). Sonographic features include a heterogeneously isoechoic, polypoid, or pedunculated endometrial mass, with an ill-defined margin, hemorrhagic foci, posterior shadowing, and associated adenomyosis in the myometrium. Knowledge of these sonographic appearances may facilitate the diagnosis of polypoid adenomyoma and help differentiate it from other polypoid uterine tumors.
Gynecology and Obstetrics Clinical Medicine · 2021 · 2 citations · open access
A clinicopathological study of 39 cases of atypical polypoid adenomyoma of the uterus
AbstractAbstract Objective To clarify the clinical and pathological characteristics of atypical polypoid adenomyoma (APA) in order to improve the criteria used to diagnose and treat this disease. Study design In 39 cases of APA, retrospective analysis was performed of theclinical data, pathological characteristics, and the follow-up findings in patients admitted to the Peking University People's Hospital from 2007 to 2019. Results The median age was 39.6 years (range 24–60 years). Thirty seven patients were premenopausal (i.e.94.9 %) and eighteen patients were nullipara (i.e. 46.2 %). Abnormal uterine bleeding was the most common presenting symptom. Hysteroscopic transcervical resection (i.e.TCR) identified lesions in 35 cases whereas: a) hysterectomy identified them in 3 cases; b) dilatation and curettage (D&C) identified them in 1 case. Immunohistochemical analysis was performed on 24 samples. In the glandular component, hormone receptors were positively expressed. In all cases, Ki67 expression was detectable in approximately 50 % of the cases. In those samples, its presence was definitive in eighteen of the nineteen cases (94.7 %,18/19), p53 positive expression was present in most cases (68.8 %,11/16), and PTEN positive expression was detected in 40 % (4/10). Stroma immunophenotype expression was exhibited as follows: a)CD10-(12/12), Desmin +(6/7); b) Vimentin +(4/4); c) α-SMA+ (3/3) and; d) p16 positve staining in of 80 %(4/5).The concurrent amount of atypical endometrial hyperplasia with atypical polypoid adenomyoma was 23.1 %(9/39), while its concurrent level of endometrial carcinoma with atypical polypoid adenomyoma was 7.7 % (3/39). Fertility preserving treatments were performed in 20 patients with strong childbearing desires. Their pregnancy success was 15 %(3/20) and the live birth frequency was 10 %(2/10). Follow-up findings were available in 36 cases (92.3 %) with a medial follow-up of 48.1 months (range 4–122 months). Its pathological recurrence and frequency of progression into endometrial carcinoma were both 5 %(1/20). One case died of another type of malignancy, while the other patients were alive. Conclusions APA occurs mostly during the years of a women's reproductive period. Its diagnosis is based on the analysis of pathological and immunohistochemical findings. Individuals diagnosed with APA are at risk to coexist with endometrial carcinoma and atypical endometrial hyperplasia. For those individuals who desire retaining fertility, the treatment strategy involves performing TCR completely remove the lesions and close follow-up for surveillance of possible progressive APA recurrence. For those individuals who have no fertility desire, hysterectomy may be a preferred option.
Journal of Biosciences and Medicines · 2018 · 1 citations · open access
Atypical Polypoid Adenomyomas of Uterus: A Clinicopathologic Study of 2 Cases
AbstractAtypical polypoid Adenomyomas (APA) is a rare benign tumour in uterine. It is would distinguished from well-differentiated endometrial adenocarcinoma because of his histological features. We report 2 cases of 31-year-old and 33-year-old patient whose symptom were abnormal uterine bleeding. The mass was pedunculated with a narrow pedicle connecting to the pedunculated with a narrow pedicle connecting to the cervical; the other was in the uterine prolapse without pedicle. The surgical procedure was polypectomy only in all two patients with hysteroscopy. The histopathology showed the lesions were composed of a proliferation of irregular atypical endometrial glands separated by varying amounts of cellular smooth-muscle stroma. No mitotic activity was observed in the epithelial or mesenchymal elements in APA. The treatment of APA should depend on the age and reproductive desire of patient.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
